NCT06502457 Pain Management With Virtual Reality Hypnosis
| NCT ID | NCT06502457 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Hypnosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 142 participants |
| Start Date | 2024-07-09 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 142 participants in total. It began in 2024-07-09 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The latency phase corresponds to the first phase of the first stage of labour, during which the parturient feels regular, rhythmic uterine contractions that are often painful, with or without changes of the cervix. This phase lasts an average of 8 hours for primiparous women, compared with 5 hours for multiparous women, and can last up to twenty hours in total. Cervical ripening corresponds to the medical induction of regular, painful uterine contractions in order to obtain a favourable cervix for the induction of labour. Cervical ripening is carried out either medically (oral or local prostaglandins) or mechanically (double balloon dilatation) and accounts for 69.2% of labour inductions, which in turn account for 25.8% of births. At Amiens-Picardie University Hospital, this maturation stage can last from a few hours to 2 days, depending on the service protocol. What these two stages of childbirth have in common is that they are both painful, with very few analgesic drugs available that can be used without side-effects on the foetus during pregnancy. In recent years, there has also been a growing demand from parturients for the use of non-medicinal therapies. It therefore seems essential to provide parturients with as many effective non-drug methods as possible to manage their pain properly. If virtual reality hypnosis sessions prove to be effective, they will provide better pain management for women in labour, reduce the use of morphine derivatives (with their attendant side-effects, particularly on the foetus), and above all meet the growing demand from women in labour for the most physiological possible support during childbirth.
Eligibility Criteria
Inclusion Criteria: * Parturient over 18 * Parturient who speaks and understands French * Parturient hospitalised prior to labour * Membranes intact or ruptured * Spontaneous or induced labour * Parturient in latency phase * Term ≥ 37SA * END \> 3 * Parturient requiring active pain management (medicinal or non-medicinal) * Low-risk pregnancy Exclusion Criteria: * Parturient under legal protection * Parturient with a hearing impairment * Parturient with visual impairment * Parturient with epilepsy * Parturient with psychiatric problems * Pathological pregnancy * Parturient with chronic pain * Parturient with addiction-related disorders * Parturient allergic to paracetamol * Parturient allergic to phloroglucinol * Parturient allergic to codeine * Parturient allergic to nalbuphine * Parturient allergic to orozamudol
Frequently Asked Questions
Who can join the NCT06502457 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Hypnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06502457 currently recruiting?
Yes, NCT06502457 is actively recruiting participants. Visit ClinicalTrials.gov or contact Centre Hospitalier Universitaire, Amiens to inquire about joining.
Where is the NCT06502457 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT06502457 clinical trial?
NCT06502457 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 142 participants.